Key result
Percutaneous renal denervation demonstrates a clear 24-hour antihypertensive effect over sham control.
Why the study?
Does percutaneous renal denervation reduce blood pressure over 24 hours in patients with poorly controlled hypertension?
Does percutaneous renal denervation reduce blood pressure over 24 hours in patients with poorly controlled hypertension?
Percutaneous renal denervation shows promise as an effective device-based therapy for reducing blood pressure over 24 hours in poorly controlled hypertension.
May support consideration in resistant hypertension; confirms 24-hour efficacy in sham-controlled trials but leaves durability open.
Percutaneous renal denervation is a novel device therapy that modifies the circulatory regulatory system and has received considerable attention recently. This treatment partially blocks the renal sympathetic nervous system, which is an organ-connecting pathway between the brain and the kidney. Denervation techniques currently under clinical investigation include radiofrequency, ultrasonic, and chemical ablation with alcohol, all of which are executed through transcatheter access to the renal artery. All recently published randomized sham-controlled trials have shown a clear antihypertensive effect of renal denervation over 24 hours, including during the nighttime and early morning. This treatment has promise in the management of poorly controlled hypertension as well as in the prevention of the development or aggravation of arrhythmias and heart failure.
No takes yet. Share an insight, caveat, or question.
Kario et al. (2021) studied this question. Percutaneous renal denervation demonstrated a clear antihypertensive effect over 24 hours in recent randomized sham-controlled trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: